Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
Crossref DOI link: https://doi.org/10.1007/s00280-015-2682-2
Published Online: 2015-01-28
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chan, Emily
Kwak, Eunice L.
Hwang, Jimmy
Heiskala, Marja
de La Bourdonnaye, Guillaume
Mita, Monica
Text and Data Mining valid from 2015-01-28